BIND Therapeutics (BIND) Tops Q2 Expectations

BIND Therapeutics (NASDAQ: BIND) reported Q2 EPS of ($0.51), $0.09 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $2.46 million versus the consensus estimate of $2.2 million.

For earnings history and earnings-related data on BIND Therapeutics (BIND) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• UBS Reiterates Buy Rating on Sysco (SYY) Following Trip to Company Headquarters
• Brinker Int'l (EAT) PT Raised to $260 at DA Davidson, Neutral Rating Maintained